
Spanish fossils may represent unknown ancient human species
March 12 (Reuters) - Scientists have unearthed in Spain fossilized facial bones roughly 1.1 million to 1.4 million years old that may represent a previously unknown species in the human evolutionary lineage - a discovery that rewrites humankind's early history in Europe.
The fossils from the Sima del Elefante cave site near the city of Burgos comprise fragments spanning 80 percent of the left side of an adult individual's middle face, including parts of the cheekbone and upper jaw with the nasal structure. They are among the oldest-known human fossils from Europe.
The researchers nicknamed the fossil "Pink," honoring the band Pink Floyd.
Pink's facial anatomy was more primitive than that of Homo antecessor, a species known to have inhabited Western Europe roughly 850,000 years ago whose slender midface resembled modern people. Pink possessed a more projected and massive midface than Homo antecessor, and displayed some similarities to - but also differences with - Homo erectus, thought to be the first human species to have migrated out of Africa.
The researchers said the fossils were not complete enough to conclude that Pink belonged to a yet-unnamed ancient human species but said this was a real possibility. They assigned the fossil the provisional name Homo affinis erectus in recognition of its affinities to certain Homo erectus traits.
"These findings open a new line of research in the study of human evolution in Europe, as they introduce a new player in the early occupation of Europe," said archaeologist Rosa Huguet of the Catalan Institute of Human Paleoecology and Social Evolution (IPHES-CERCA) in Spain, lead author of the study published on Wednesday in the journal Nature, opens new tab.
"When we have more fossil remains, we will be able to say more about this species," Huguet said.
Our species Homo sapiens did not appear until roughly 300,000 years ago in Africa, later migrating worldwide, including into Europe. Homo erectus first appeared in Africa roughly 1.9 million years ago, with body proportions similar to modern people. Homo antecessor also had modern body proportions as well as modern-looking facial anatomy.
Pink's midface resembles Homo erectus with its flat and underdeveloped nasal structure, unlike the prominent nasal bone structure of Homo antecessor and Homo sapiens.
"Homo antecessor has a modern-like midface, very similar to that of Homo sapiens. In contrast, the midface found at the Sima del Elefante site has a combination of features shared with Homo erectus and others that are derived and not present in Homo erectus," said paleoanthropologist and study senior author José María Bermúdez de Castro Risueño, co-director of the Atapuerca Project focused on human evolution.
Little is known about Europe's earliest human residents. There are fossils commonly attributed to Homo erectus dating to 1.8 million years ago at a Caucasus site in Georgia called Dmanisi on the fringes of Europe. There also are stone tools dating to 1.4 million years ago from western Ukraine, and bones with cut marks, suggesting the use of stone tools to butcher animal carcasses, dating to 1.95 million years ago from Romania.
At the Sima del Elefante site, researchers previously recovered a jawbone fragment estimated at 1.2 million years old, though the species was undetermined. The Pink fossils found in 2022 were recovered in a deeper - thus older - layer at the same site. A child's molar dating to approximately the same time is known from a site near Granada in Spain, with the species also unclear.
"There are very few sites with human fossils corresponding to the first settlers of Europe," said archaeologist and study co-author Xosé Pedro Rodríguez-Álvarez of the University of Rovira I Virgili in Spain.
Pink is older than any known Homo antecessor remains. And Pink's species, according to the researchers, may belong to a population that reached Europe during a migration predating that of Homo antecessor.
"We do not know if they could have coexisted for a short period of time or if they never lived together," Huguet said.
Discovered nearby Pink were simple quartz and flint tools and animal bones with cut marks indicating butchery.
The researchers have not been able to reconstruct Pink's full face because of the incompleteness of the fossils. Diligent work was needed to assemble the fragments to reveal the midface, combining traditional conservation and restoration methods with sophisticated imaging and 3D analysis. Pink's gender remains unclear.
"There are many questions to be answered, and this find helps to write a new page in the history of human evolution," Bermúdez de Castro said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
8 hours ago
- Reuters
Russia says it tests new laser defences against drones
MOSCOW, June 13 (Reuters) - Russia said on Friday it had conducted large-scale tests of new laser-based systems to defend against drones. A government statement described the new technology as "promising" and said it had been tested against various types of drone in different weather conditions. It said the anti-drone lasers would become part of a "universal air defence system" that President Vladimir Putin said this week Russia needed to build. "The test results will be used to refine existing models and create systems capable of providing reliable protection against modern air attack weapons. Conducting tests allows us to move on to serial production and upscaling," the statement said. An accompanying video showed charred debris from a destroyed drone. Both sides have deployed drones on a huge scale in the Russia-Ukraine war, using them to spot and hit targets not only on the battlefield but way beyond the front lines. Ukrainian drones have frequently struck sites deep inside Russia such as oil depots, refineries and airfields, highlighting the need for Moscow to boost its defences. Earlier this month, Ukrainian drones smuggled close to air bases in trucks inflicted serious damage to Russia's long-range bomber fleet.


Scottish Sun
2 days ago
- Scottish Sun
‘Game changing' fat jabs WON'T help you lose as much weight as you think, scientists discover
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) SO-CALLED 'miracle' weight-loss jabs are far less effective in the real world than in clinical trials, a major study has revealed. The new findings could have big implications for Brits considering the injections, which have soared in popularity across the UK in recent years. Sign up for Scottish Sun newsletter Sign up 2 In a 'real-world' setting people might lose less weight in a regular clinical setting than during clinical trials Credit: Alamy 2 The drugs work best when people stick to them and take the full recommended dose Credit: Reuters Until now, the jabs have been hailed as an easier alternative to classic weight loss methods like calorie counting, weight watchers and the gym. But researchers at the Cleveland Clinic in the US found average weight loss on the jabs in the 'real world' is just 6.9 per cent after a year. This is less than half the amount typically seen in clinical trials, where patients often lose 15 per cent with semaglutide, the ingredient in Wegovy, and up to 22.5 per cent with tirzepatide, found in Mounjaro. The study, published on Tuesday in Obesity, followed 7,881 adults with severe obesity who started semaglutide or tirzepatide between 2021 and 2023. It discovered the drugs worked best when people stuck to them and took the full recommended dose, but in the real world, that rarely happened. More than one in five patients (21 per cent) stopped taking the jabs within the first three months, and another 32 per cent quit between three and 12 months. Meanwhile, over 80 per cent were on lower-than-recommended maintenance doses, needed to keep the weight off. Those who quit early lost just 3.6 per cent of their body weight. Patients who stayed on the treatment for a full year lost 11.9 per cent on average. The best results were seen in people who stayed on full doses, who lost 13.7 per cent with semaglutide and 18 per cent with tirzepatide. GP-approved tips to really lose weight safely - and keep it off 'Our findings could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions," Dr Hamlet Gasoyan, lead author of the study, said. Among the 1,320 people with prediabetes, the precursor to type 2 diabetes, at the start of the study, those who stayed on the jabs were also far more likely to reverse the condition. Don't stop the drugs early These medications work by copying a natural hormone found in the body called GLP-1. This hormone helps people feel fuller for longer, which reduces appetite and helps with weight loss. It also helps control blood sugar by telling the pancreas to make more insulin and slowing down how quickly sugar from food gets into the bloodstream. That's why these drugs are effective at both preventing type 2 diabetes and helping people shed pounds. Just 33 per cent of early quitters returned to normal blood sugar levels, compared with 68 per cent of those who stayed on the medication. 'Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important,' Dr Gasoyan said. 'This study highlights that treatment discontinuation, especially early, negatively affects both weight and glycemic control outcomes.' The most common reasons for stopping the jabs were cost, insurance issues, side effects and shortages, it said, The experts said a follow-up study is planned to dig deeper into why patients quit, and what happens to their weight afterwards.


Reuters
3 days ago
- Reuters
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study
June 11 (Reuters) - Novavax's (NVAX.O), opens new tab experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune responses in some patients tested in a late-stage study, the company said on Wednesday.